Displaying 1121 - 1140 of 1557
Danaher Corporation and MDS, Inc., In the Matter of
The Commission challenged Danaher’s proposed acquisition of MDS Analytical Technologies, requiring that MDS divest its assets related to its laser microdissection business. The proposed settlement is designed to preserve competition in the North American market for laser microdissection devices – a key tool for scientific research.
Administrative Law Judge Rules That Polypore International's 2008 Acquisition of Rival Battery Separator Manufacturer Violated Antitrust Law
Service Corporation International, In the Matter of
The Commission challenged Service Corporation International's (SCI) proposed acquisition of local rival Palm Mortuary, Inc. At the time of the acquisition, SCI, the nation’s largest cemetery operator, was the third-largest provider of cemetery services in Las Vegas, Nevada, and after the acquisition of Palm, would have controlled 76 percent of hte market for funeral services, which includes burial plots, opening and closing of graves, memorials, burial vaults, mausoleum spaces, and cemetery maintenance. The Commission's order required SCI to sell its cemetery and funeral home in Las Vegas to complete the acquisition of Palm.
Horizontal Merger Guidelines Review Project
Watson Pharmaceuticals, Inc., a corporation, and Robin Hood Holdings Limited, a limited liability company, In the Matter of
The Commission charged that Watson Pharmaceuticals, Inc.’s acquisition of Robin Hood Holdings Limited, owner of Arrow Pharmaceuticals, would have harmed consumers by eliminating future competition for important generic drugs used to treat Parkinson’s disease (cabergoline) and the side effects of chemotherapy (dronabinol). The Commission’s order requires the firms to sell assets related to the two drugs to FTC-approved buyers and to ensure the acquirers have the means to compete effectively in the future.
There is a related federal proceeding and two related administrative proceedings:
Horizontal Merger Guidelines Review Project
FTC's Closure of Its Investigation of Consummated Hospital Merger in Temple, Texas
Horizontal Merger Guidelines Review Project
Horizontal Merger Guidelines Review Project
Horizontal Merger Guidelines Review Project
FTC Order Preserves Competition Lost Through SCI's Acquisition of Palm Mortuary
K+S Aktiengesellschaft and International Salt Company LLC, In the Matter of
The FTC announced a consent order that will maintain competition in the market for bulk de-icing road salt in Maine and Connecticut that otherwise would have been lost as a result of K+S Aktiengesellschaft’s (K+S) $1.68 billion proposed acquisition of Morton International, Inc. To protect state and local governments from higher prices, the order requires K+S’s U.S. subsidiary, International Salt Company LLC (ISCO), to sell its bulk de-icing salt assets in Maine to Eastern Salt Company, Inc., and to sell a similar set of assets in Connecticut to Granite State Minerals, Inc.
Aspen Technology, Inc., In the Matter of
Under terms of the order, Aspen agreed to divest Hypotech’s continuous process and batch process assets and Aspen’s operator training software and service business to a Commission-approved buyer to settle charges in the complaint and resolve the administrative proceedings. The Commission issued an administrative complaint on August 6, 2003 that challenged Aspen’s 2002 acquisition of Hyprotech, Ltd. alleging that the acquisition eliminated a significant competitor in the provision of process engineering simulation software for industry. According to the complaint, the acquisition has led to reduced innovation competition in six specific process engineering simulation software markets.
Thoratec Corporation, and HeartWare International, Inc., In the Matter of
The Commission authorized a preliminary injunction to block Thoratec Corporation’s proposed $282 million acquisition of rival medical device maker HeartWare International, Inc., charging that the transaction would substantially reduce competition in the U.S. market for left ventricular devices (LVADs), a life-sustaining treatment for patients with advanced heart failure. The FTC’s administrative complaint alleges that Thoratec seeks to maintain its monopoly by acquiring HeartWare, thus eliminating the only significant threat to Thoratec’s continued dominance of the LVAD market. In August of 2009, the parties announced they would not to proceed with the proposed acquisition, and the Commission dismissed the Administrative Complaint without filing an motion for preliminary injunction in federal court.
Commission Approves FY 2008 HSR Premerger Notification Report; FTC Approves Final Consent Order in Matter Concerning Alta Bates Medical Group
FTC Adds Requirements to 2004 Order to Restore Competition in Process Simulation Software Market
CSL Limited, a corporation, and Cerberus-Plasma Holdings, LLC, In the Matter of
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. Following the FTC's lawsuit to block the transaction, CSL Limited announced that it would not proceed with its proposed acquisition.
Displaying 1121 - 1140 of 1557